At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 466 enrolled
Drug / intervention
RTX-GRT7039 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Phase III Trial, to Evaluate the Efficacy and Safety of a Single Intra-articular Injection of RTX-GRT7039 in Adult Subjects With Pain Associated With Osteoarthritis of the Knee
In Brief
A Phase 3 clinical trial evaluating RTX-GRT7039 and Placebo for Osteoarthritis. Completed, enrolled 466 participants across 81 sites in 5 countries.
Detailed Summary
A double-blind, randomized, placebo-controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of single injection of RTX-GRT7039 versus placebo in patients who have pain associated with osteoarthritis of the knee despite standard of care.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis
CountriesDenmark, Portugal, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedJul 2022
Enrollment StartSep 2022
Primary CompletionAug 2024
TodayJul 2026
First PostedJul 8, 2022
Enrollment StartSep 26, 2022
Primary CompletionAug 15, 2024
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 4.0 years ago
Interventions
RTX-GRT7039drug
RTX-GRT7039 intra-articular injection.
Placebodrug
Placebo matching RTX-GRT7039 intra-articular injection.